Ann: Notice of Extraordinary General Meeting/Proxy Form, page-103

Hi tj2,

I have limited experience with this (once again via CUV) it’s a bit dated however I’m happy to share.
https://www.asx.com.au/asxpdf/20151124/pdf/43378f6hzwd6v9.pdf

Clinuvel have been considering a NASDAQ listing for many years and back in 2015 they shared some of there analysis. The long and short of it, not possible to state definitively if better or worse to dual list however most pre-revenue biotech (pharma or medical device) companies are worse off by listing on the NASDAQ in addition to the ASX.

Note: CUV still hasn’t taken the plunge to list on the NASDAQ despite several years of revenue and a couple in profit (they would probably qualify for the highest tier NASDAQ classification).

I’m not sure AHZ would even qualify for the lowest NASDAQ tier and I don’t see a consolidation and US listing as adding any real value to the company. I’d be much happier to see a large investment (at a slight premium) from proven Med-tech investors, the likes of the early stage investors behind 4C and CoreValve (provided it wasn’t a conflict of interest with current investments of course).